Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Next Previous
Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Alternative Names: CERVAVAC; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Serum Institute of India; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Serum Institute of India; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Serum Institute of India; qHPV vaccine - Serum Institute of India; Recombinant quadrivalent HPV vaccine - Serum Institute Of India; SIIPL qHPV vaccine; Tetravalent HPV vaccine - Serum Institute of India

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serum Institute of India
  • Developer Bill & Melinda Gates Foundation; Biotechnology Industry Research Assistance Council; Department of Biotechnology (India); Serum Institute of India
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer

Most Recent Events

  • 04 Mar 2024 Serum Institute of India plans a phase III trial for Human papillomavirus infection (Prevention) in Kenya, Mozambique and South Africa in June 2024 (NCT06281119)
  • 24 Jan 2023 Launched for Cervical cancer (Prevention) in India (IM)
  • 01 Sep 2022 The Serum Institute Of India (SII) enters into a partnership agreement with Department of Biotechnology (DBT) and Bill and Melinda Gates Foundation for the development of Human papillomavirus vaccine recombinant quadrivalent, prior to September 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top